| ●Editorial | Tsubaki H | 464 | Full text | |
| ●Round table discussion | ||||
| Perspectives for overcoming the COVID-19 pandemic: Science, society, and medicine | Tsubaki H，Funatogawa I， Saito M，Endo K，Kasanuki H |
465-530 | Full text | |
| ・Forum COVID-19 Response | ||||
| Confronting the third wave of the COVID-19 pandemic in Japan A proposal of two policies: Official Coronavirus Screening and data-driven approach | Kasanuki H | 531-4 | Full text | |
| ●Original article | ||||
| Considering the future of clinical research at the turning point of implementation of the new legislation in Japan －Consideration of flexible use of clinical evidence and current Japanese regulations; Lessons learned from the COVID-19 pandemic－ | Ohshima H，Aoyagi M， Tajima M，et al． |
535-49 | Full text | |
| ●Webinar | ||||
| COVID-19 and bioethics: Part1 Ethical Challenges and COVID-19 The Recommendation No. 01/2020 of the Brazilian Society of Bioethics (SBB) |
Greco D Co-organized by the COVID-19 Task Force, Japan Association for Bioethics & Brazilian Society of Bioethics |
551-74 | Abstract | |
| ・Translation | ||||
| Brazilian Society of Bioethics (SBB) Recommendation No. 01/2020 | Brazilian Society of Bioethics | 575-82 | Full text | |
| ●Translations and explanatory articles | ||||
| Development and Licensure of Vaccines to Prevent COVID-19 Guidance for Industry |
U.S. Department of Health and Human services Food and Drug Administration Center for Biologics Evaluation and Research （Trans. by Saio T，Kurihara C） |
583-602 | ||
| On the FDA Guidance for COVID-19 Vaccine development | Kurihara C，Saio T | 603-7 | Abstract | |
| ●Articles | ||||
| Therapist drift: which is important experience or technique? | Saio T | 609-24 | Abstract | |
| On the death of a study subject in the first in human trial of E2082 | Saio T | 625-42 | Full text | |
| ●Forum | ||||
| The future of medicines development and the professional development for public engagement | Imamura K，Tsutsumi N | 643-8 | Full text | |
| ●Instructions for authors［Japanese］＆［English］ | 649-57 | Full text | ||
| ●Editor’s note | Nudeshima J | 659 | Full text | |
| [Electronic publications only] | ||||
| ●Webinar | ||||
| －COVID-19 and bioethics－ Part1 Ethical Challenges and COVID-19: The Recommendation No. 01/2020 of the Brazilian Society of Bioethics（SBB） | Dirceu Greco Co-organized by the COVID-19 Task Force, Japan Association for Bioethics ＆ Brazilian Society of Bioethics |
661-84 | Full text | |